Private Placements





Hedge Funds





Uvax Bio, Inc.




Business: Vaccines targeting infectious diseases.


Industry/Market: $47B in current annual worldwide sales of existing approved vaccines with $20B predicted for 2021 in sales for COVID-19 vaccines alone. Traditionally a relatively small segment of the overall biopharmaceutical industry, vaccines and their role in meeting emergent health challenges have recently been underscored in importance, and it is likely the trend will increase with unprecedented global attention.


Status: Uvax Bio has a robust pipeline of more than nine vaccine candidates ready to advance to clinical trials including COVID-19, HIV, RSV, HCV, Ebola, Influenza, Lassa, Malaria, and Tuberculosis.




The proprietary technology is licensed from The Scripps Research Institute. Our paradigm-shifting 1c-SApNP (single-component self-assembling protein nanoparticle) vaccine platform combines structure-based optimization of antigens with nanoparticle engineering and consists pf three integrated components:


(i) An Optimized Antigen (UvaxAG) that elicits a strong protective immune response.


(ii) A protein nanoparticle (pNP) that displays 20 of the optimized antigens in precise geometry, contains structural and functional helper elements, and is engineered to a size that is easily recognized by the human immune system.


(iii) A one-for-all bio-manufacturing process enabled by a single-component (1c) that genetically encodes the entire vaccine particle.




The most-advanced vaccine candidate, UvaxAg I3-01 is undergoing CMC-manufacturing and IND-enabling studies. A pre-IND meeting is anticipated by the end of 2020 with first-in-human planned for 2Q2021. Uvax Bio has partnered with Abzena (San Diego, CA) for CMC-manufacture and ICON plc (Dublin, Ireland) to support the IND-preparation and filing.




$15M in NIH grants to Scripps Research supported discovery and early research for HIV-1, HCV, SARS (now SARS-CoV-1), and MERS vaccine candidates.




Two allowed and five pending patents covering specific target antigen designs and the platform technology filed by The Scripps Research Institute (TSRI) and licensed to Uvax Bio with global and sublicense rights.




$17M combined seed and pre-IPO funding in convertible debt.






Ji Li, PhD. CEO, President, & Co-Founder.




Mark Blomquist. Chief Financial Officer.




Linling He, PhD. Executive Vice President & Chief Technical Officer.




John Moroney. Executive Vice President of Business Development.




Colette Saccomanno, PhD, MSLIS. Senior Vice President of Corporate Affairs.


Scientific Advisory Board:




Jiang Zhu, PhD, Chair of the Scientific Advisory Board, Co-Founder & Co-Inventor. Professor, Departments of Immunology & Microbiology and Integrative Structure & Computational Biology, The Scripps Research Institute, La Jolla, CA.




Ian Wilson, DPhil. Professor & Chair, Department of Integrative Structure & Computational Biology, The Scripps Research Institute, LaJolla, CA.




Drew Weismann, MD, PhD. Professor & Chair, Department of Integrative Medicine, Perelman School of Medicine of the University of Pennsylvania.




Robin Shattock, PhD. Professor & Head of Mucosal Infection & Immunity, Department of Medicine, Imperial College of London.


Offering: Pre-IPO financing.




Offices: 3801 Kennett Pike, Suite A101, Wilmington, DE 19807-9998


Contact: Ji Li, PhD, CEO/President. 302.364.0363 or




Index of Private Placements & Hedge Funds




Here is a link to information on our comprehensive investor awareness program.

For more detailed information, please contact one of the following individuals:


William J. Ritger at 561.891.1903 or

David Goodboy at 561.349.7300 or



The Deal Flow section of this website is operated jointly by Palm Beach Hedge Fund Association, Inc., a Florida corporation, and TickerBuzz, LLC, a Florida limited liability company. Neither PBHFA nor TickerBuzz are registered broker-dealers, and they do not give investment advice, endorsement, analysis, or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this site is the responsibility of the applicable issuer of such securities. Neither PBHFA nor TickerBuzz have taken any steps to verify the adequacy, accuracy, or completeness of any information, and neither PBHFA nor TickerBuzz nor any of their officers, directors, agents, and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the PBHFA Terms of Use and Privacy Policy. Neither PBHFA nor TickerBuzz make investment recommendations, and no communication, through this website or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development, and their business model, products, and services may not yet be fully developed, operational, or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. In the most sensible investment strategy for start-up investing, start-ups should only be part of your overall investment portfolio. Further, the start-up portion of your portfolio may include a balanced portfolio of different start-ups. Investments in start-ups are highly illiquid, and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.


This Profile is intended for discussion purposes only; the only definitive source of information regarding this offering is the Company offering documents. This Profile is not a solicitation to buy or sell any security, and must not be relied upon for financial, legal, tax, or any other professional advice. Investor prospects should also carefully research and consider the risks inherent in this investment. The information in this Profile is applicable only as of the date of this Profile and is subject to change without prior notice. Past performance is not indicative of future results. The editor of this Profile is a Managing Member of TickerBuzz. This Company has not paid any fee to either PBHFA or TickerBuzz for this Company Profile. Neither PBHFA nor TickerBuzz take any compensation relating to the success of any securities offering. November 2, 2020.




Web Hits